Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Multiple Myeloma 4Lymphoma 3Glioblastoma 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Glioblastoma × marizomib × Clear all
NCT03345095 2025-07-01

MIRAGE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
749 enrolled 15 charts
CNS

Glioblastoma

NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Celgene

Phase 1/2 Completed
121 enrolled 27 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02903069 2021-04-19

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Celgene

Phase 1 Completed
66 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡